Each film coated tablet contains:
Sitagliptin (as Phosphate Monohydrate)… 50mg
Admit (Sitagliptin) is indicated in patients with type II diabetes mellitus (Non-insulin Dependent Diabetes Mellitus) as an adjunct to diet and exercise to improve glycemic control as mono-therapy or combination therapy or in combination with insulin. Admit (Sitagliptin) may be prescribed in combination with metformin or with sulfonylurea or with a PPAR agonist (Thiazolidinediones) when the treatment with the single agent alone (with diet and exercise) does not provide adequate glycemic control. Admit (Sitagliptin) may be prescribed in combination with metformin and a sulfonylurea or with metformin and a PPAR (Thiazolidinedione) when dual therapy with these agents (with diet and exercise) does not provide adequate glycemic control.
Available in pack of 1 x 14 tablets